Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis
Authors:
- 1 January 2015
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 191 (1) , 110-113
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Pivotal Role of Matrix Metalloproteinase 13 in Extracellular Matrix Turnover in Idiopathic Pulmonary FibrosisPLOS ONE, 2013
- Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: Test Properties and Minimal Clinically Important DifferenceAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Pirfenidone in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2009
- Idiopathic pulmonary fibrosisOrphanet Journal of Rare Diseases, 2008
- Classification and Natural History of the Idiopathic Interstitial PneumoniasProceedings of the American Thoracic Society, 2006
- Disorders of lung matrix remodelingJournal of Clinical Investigation, 2004
- Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2003